Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.62 |
| ▸ | IL1RN | P18510 | 1/20 | 0.62 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.61 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.59 |
| ▸ | NPY1R | P25929 | 1/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577265 | 0.94 | ERAP1 (0.66) | ERAP2IL1RNERAP1LNPEPOPRM1 | |
| SCHEMBL30010303 | 0.94 | ERAP1 (0.68) | ERAP2IL1RNERAP1LNPEPOPRM1 | |
| SCHEMBL30010730 | 0.94 | ERAP1 (0.66) | ERAP2IL1RNERAP1LNPEPOPRM1 | |
| SCHEMBL30011658 | 0.94 | ERAP1 (0.66) | ERAP2IL1RNERAP1LNPEPOPRM1 | |
| SCHEMBL29577668 | 0.94 | ERAP1 (0.68) | ERAP2IL1RNERAP1LNPEPOPRM1 | |
| SCHEMBL29577129 | 0.94 | ERAP1 (0.68) | ERAP2IL1RNERAP1LNPEPOPRM1 | |
| SCHEMBL29577971 | 0.93 | OPRM1 (0.67) | ERAP2IL1RNERAP1LNPEPOPRM1 | |
| SCHEMBL29577215 | 0.93 | OPRM1 (0.67) | ERAP2IL1RNERAP1LNPEPOPRM1 | |
| SCHEMBL29578343 | 0.93 | OPRM1 (0.67) | ERAP2IL1RNERAP1LNPEPOPRM1 | |
| SCHEMBL29578349 | 0.93 | OPRM1 (0.67) | ERAP2IL1RNERAP1LNPEPOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| CN-116970080-B | Anti-human MFAP5 monoclonal antibody and preparation method thereof, polynucleotide molecule, expression vector and host cell | 优睿赛思(武汉)生物科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4218815-A2 | USE OF ANTI IL-1BETA ANTIBODIES | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | IL1A, IL1R1, FCGR2A | ERAP2 3248/4885IL1RN 7/4885ERAP1 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.